Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.32 |
| ▸ | BAD | Q92934 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2680 | 0.84 | — | — | |
| SCHEMBL268687 | 0.82 | CYP2A6 (0.45) | TSHRMAOBCYP2A6MAOAMAPT | |
| SCHEMBL29263188 | 0.82 | MAOB (0.40) | TSHRMAOBCYP2A6MAOAKDM1A | |
| SCHEMBL452179 | 0.76 | TSHR (0.46) | TSHRMAOBCYP2A6MAOAKDM1A | |
| SCHEMBL11328700 | 0.72 | TSHR (0.60) | TSHRMAOBCYP2A6MAOAKDM1A | |
| SCHEMBL8345063 | 0.72 | HTR2C (0.41) | TSHRMAOBMAPTHTR2CSIGMAR1 | |
| SCHEMBL4132391 | 0.70 | TSHR (0.50) | TSHRMAOBCYP2A6MAOAKDM1A | |
| SCHEMBL4132386 | 0.70 | TSHR (0.50) | TSHRMAOBCYP2A6MAOAKDM1A | |
| SCHEMBL5713754 | 0.69 | PNMT (0.37) | KDM1AMAPTL3MBTL1HTR2C | |
| SCHEMBL19926341 | 0.69 | KDM1A (0.35) | KDM1AACHECYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | claimed |
| EP-3863711-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2021-08-18 | — | — | EP | claimed |
| EP-3802467-A1 | SPIROCYCLIC COMPOUNDS | C4 Therapeutics, Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| EP-3475262-B1 | BICYCLIC IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF RENAL DISEASE, CARDIOVASCULAR DISEASES AND FIBROTIC DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-24 | — | — | EP | claimed |
| EP-3781162-A1 | EP4 INHIBITORS AND USE THEREOF | Arrys Therapeutics, Inc. (US) | 2021-02-24 | — | — | EP | claimed |
| EP-3749650-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO Pharma (FR) | 2020-12-16 | — | — | EP | claimed |
| WO-2019204257-A1 | EP4 INHIBITORS AND USE THEREOF | Arrys Therapeutics, Inc. (US) | 2019-10-24 | — | — | WO | claimed |
| WO-2019154956-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | claimed |
| CN-1694870-A | Acetyl 2-hydroxy-1, 3-diaminoalkanes | PHARMACIA & UPJOHN CO LLC (US) | 2005-11-09 | — | — | CN | claimed |
| CN-1198839-C | Novel dipeptide amidines as thrombin inhibitors | AIBET GMBH & CO KG (DE) | 2005-04-27 | — | — | CN | claimed |
| CN-1175953-A | Novel dipeptide amidines as thrombin inhibitors | BASF AG (DE) | 1998-03-11 | — | — | CN | claimed |
| CN-118271341-A | Menin inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20240199619-A1 | WEE1 INHIBITOR AND USE THEREOF | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2024-06-20 | — | — | US | disclosed |
| CN-115197196-B | TYK2 inhibitor and application thereof | 扬子江药业集团有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-118176192-A | Degradation agent and application thereof | 成都先导药物开发股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-1735408-A | Receptor function controlling agent | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-15 | — | — | CN | disclosed |
| CN-1198839-C | Novel dipeptide amidines as thrombin inhibitors | AIBET GMBH & CO KG (DE) | 2005-04-27 | — | — | CN | disclosed |
| CN-1175953-A | Novel dipeptide amidines as thrombin inhibitors | BASF AG (DE) | 1998-03-11 | — | — | CN | disclosed |
| CN-1015259-B | PREPARATION OF PERHYDROTHIAZEPINE DERIVATIVE | SANKYO CO (JP) | 1992-01-01 | — | — | CN | disclosed |
| CN-85107472-A | The preparation method of perhydrothiazepine derivative | — | 1987-05-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | NLRP3, NLRP1, PYCARD | TSHR 2360/4885MAOB 1327/4885CYP2A6 2890/4885 |
| US-20240199619-A1 | WEE1 INHIBITOR AND USE THEREOF | WEE1, WEE2, PPME1 | TSHR 4429/4885MAOB 3997/4885CYP2A6 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.